Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon alfa-2b

Heinz L. Seewann , Ronald Zikulnig , Gertraud Gallhofer , Christine Schmid
{"title":"Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon alfa-2b","authors":"Heinz L. Seewann ,&nbsp;Ronald Zikulnig ,&nbsp;Gertraud Gallhofer ,&nbsp;Christine Schmid","doi":"10.1016/0277-5379(91)90576-Y","DOIUrl":null,"url":null,"abstract":"<div><p>Thirty-six patients with chronic myeloproliferative disorders (CMPD) with thrombocytosis (essential thrombocythaemia 19 patients, chronic megakaryocytic granulocytic myelosis five, polycythaemia vera six, chronic myelogenous leukaemia six) were treated with interferon alfa-2b to reduce the platelet count. The pre-treatment platelet count was in the range 450–700 × 10<sup>9</sup>/L in eight patients, 700–1000 × 10<sup>9</sup>/L in eight and above 1000 × 10<sup>9</sup>/L in 20. In the induction phase of treatment 22 patients were treated with interferon alfa-2b 3 million units (MU) daily subcutaneously for 2 months or until the platelet count returned to normal, if earlier. Fourteen patients received 5 MU interferon alfa-2b daily in the same way. In the maintenance phase the doses were reduced to 3 MU and 5 MU thrice weekly, respectively. Complete response (CR), defined as a reduction of platelet count to below 450 × 10<sup>9</sup>/L, was achieved in 78% of patients (within 2 months of induction in 64%). The platelet depleting effect was dose dependent: CR in 2 months in 52% on 3 MU interferon alfa-2b versus 75% on 5 MU. Reduction of interferon dose was followed by an increase in platelet count in 39% of patients. The white cell count fell by 50% in Philadelphia-negative CMPD. Side effects were common, though generally mild, but led to withdrawal of treatment in six patients. Three patients suffered cerebrovascular events during treatment and one shortly thereafter.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90576-Y","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/027753799190576Y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 14

Abstract

Thirty-six patients with chronic myeloproliferative disorders (CMPD) with thrombocytosis (essential thrombocythaemia 19 patients, chronic megakaryocytic granulocytic myelosis five, polycythaemia vera six, chronic myelogenous leukaemia six) were treated with interferon alfa-2b to reduce the platelet count. The pre-treatment platelet count was in the range 450–700 × 109/L in eight patients, 700–1000 × 109/L in eight and above 1000 × 109/L in 20. In the induction phase of treatment 22 patients were treated with interferon alfa-2b 3 million units (MU) daily subcutaneously for 2 months or until the platelet count returned to normal, if earlier. Fourteen patients received 5 MU interferon alfa-2b daily in the same way. In the maintenance phase the doses were reduced to 3 MU and 5 MU thrice weekly, respectively. Complete response (CR), defined as a reduction of platelet count to below 450 × 109/L, was achieved in 78% of patients (within 2 months of induction in 64%). The platelet depleting effect was dose dependent: CR in 2 months in 52% on 3 MU interferon alfa-2b versus 75% on 5 MU. Reduction of interferon dose was followed by an increase in platelet count in 39% of patients. The white cell count fell by 50% in Philadelphia-negative CMPD. Side effects were common, though generally mild, but led to withdrawal of treatment in six patients. Three patients suffered cerebrovascular events during treatment and one shortly thereafter.

干扰素α -2b治疗慢性骨髓增生性疾病的血小板增多症
对36例合并血小板增多的慢性骨髓增生疾病(CMPD)患者(原发性血小板增多症19例,慢性巨核粒细胞性骨髓增生症5例,真性红细胞增多症6例,慢性粒细胞性白血病6例)进行干扰素α -2b治疗,以降低血小板计数。治疗前血小板计数450 ~ 700 × 109/L 8例,700 ~ 1000 × 109/L 8例,1000 × 109/L以上20例。在诱导治疗阶段,22例患者每天皮下注射300万单位(MU)干扰素α -2b治疗2个月或直到血小板计数恢复正常(如果更早)。14例患者每日以相同方式给予5 μ干扰素α -2b。在维持期,剂量分别减少到3 MU和5 MU,每周3次。78%的患者达到完全缓解(CR),定义为血小板计数降至450 × 109/L以下(64%的患者在诱导后2个月内)。血小板消耗作用是剂量依赖性的:干扰素α -2b组2个月CR为3mu组52%,而干扰素α -2b组为5mu组75%。干扰素剂量减少后,39%的患者血小板计数增加。费城CMPD阴性患者白细胞计数下降50%。副作用是常见的,虽然通常轻微,但导致6名患者退出治疗。3名患者在治疗期间发生脑血管事件,1名患者在治疗后不久发生脑血管事件。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信